Hideki Furuya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hideki Furuya has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Genichiro Ishii
Department of Pathology and Clinical Laboratories National Cancer Center Hospital East Kashiwa Japan
21 shared publications - Masashi Wakabayashi
Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan
21 shared publications - Tetsuro Taki
Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
21 shared publications - Joji Samejima
Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan
14 shared publications - Hiroyoshi Nishikawa
Division of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan
13 shared publications - Jun Matsubayashi
Department of Anatomic Pathology, Tokyo Medical University, Tokyo 160-8402, Japan
13 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 1. Correlation between tumor shrinkage and number of genetic variants. Correlation analysis of tumor shrinkage versus the number of gene mutations in the specimens obtained from (a) cohort 1 and (b) cohort 2.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 1. Correlation between tumor shrinkage and number of genetic variants. Correlation analysis of tumor shrinkage versus the number of gene mutations in the specimens obtained from (a) cohort 1 and (b) cohort 2.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 3. Progression-free survival. Kaplan-Meier estimates of progression-free survival in (a) cohort 1 and (b) cohort 2. Disease progression was reported for 2 patients in cohort 1 and 3 patients in cohort 2.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 3. Progression-free survival. Kaplan-Meier estimates of progression-free survival in (a) cohort 1 and (b) cohort 2. Disease progression was reported for 2 patients in cohort 1 and 3 patients in cohort 2.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 2. Correlation between tumor shrinkage and tumor mutational burden (TMB). Correlation analysis of tumor shrinkage versus TMB in (a) cohort 1 and (b) cohort 2.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 2. Correlation between tumor shrinkage and tumor mutational burden (TMB). Correlation analysis of tumor shrinkage versus TMB in (a) cohort 1 and (b) cohort 2.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 5. Baseline immune-cell infiltration according to BRCA1/2 mutation status. Baseline immune-cell infiltration was compared between pretreatment biopsy samples from patients with BRCA1-mutated and BRCA2-mutated tumors using immunohistochemistry. CD3+, CD4+, CD8+, FOXP3+, CD20+, and CD204+ cells, as well as tertiary lymphoid structures (TLSs), were quantified and compared between the two groups. No statistically significant differences were observed in any of the evaluated immune-cell populations or TLSs between BRCA1-and BRCA2-mutated tumors. P values are shown for each comparison.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 5. Baseline immune-cell infiltration according to BRCA1/2 mutation status. Baseline immune-cell infiltration was compared between pretreatment biopsy samples from patients with BRCA1-mutated and BRCA2-mutated tumors using immunohistochemistry. CD3+, CD4+, CD8+, FOXP3+, CD20+, and CD204+ cells, as well as tertiary lymphoid structures (TLSs), were quantified and compared between the two groups. No statistically significant differences were observed in any of the evaluated immune-cell populations or TLSs between BRCA1-and BRCA2-mutated tumors. P values are shown for each comparison.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 1. Representativeness of Study Participants.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 1. Representativeness of Study Participants.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 4. Compartment-specific immunohistochemical analysis of immune-cell infiltration before and after treatment. Quantification of immune-cell infiltration and tertiary lymphoid structures (TLSs) in paired baseline biopsy and posttreatment surgical specimens. a, b, Tumor-compartment infiltration of CD3+, CD4+, CD8+, FOXP3+, and CD20+ lymphocytes, CD204+ macrophages, and TLSs in a, Cohort 1 and b, Cohort 2. c, d, Stromal-compartment infiltration of CD4+, CD8+, and FOXP3+ cells in c, Cohort 1 and d, Cohort 2. e, f, CD4/CD8 and FOXP3/CD8 ratios in e, the tumor compartment and f, the stromal compartment. Comparisons were performed between pretreatment baseline samples and posttreatment surgical samples.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Figure 4. Compartment-specific immunohistochemical analysis of immune-cell infiltration before and after treatment. Quantification of immune-cell infiltration and tertiary lymphoid structures (TLSs) in paired baseline biopsy and posttreatment surgical specimens. a, b, Tumor-compartment infiltration of CD3+, CD4+, CD8+, FOXP3+, and CD20+ lymphocytes, CD204+ macrophages, and TLSs in a, Cohort 1 and b, Cohort 2. c, d, Stromal-compartment infiltration of CD4+, CD8+, and FOXP3+ cells in c, Cohort 1 and d, Cohort 2. e, f, CD4/CD8 and FOXP3/CD8 ratios in e, the tumor compartment and f, the stromal compartment. Comparisons were performed between pretreatment baseline samples and posttreatment surgical samples.
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 2. Chemotherapy response scores.
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Supplementary Table 2. Chemotherapy response scores.
- 30 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4580-4591
Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Purpose: Preclinical studies suggest that poly (ADP-ribose) polymerase inhibition enhances tumor immunogenicity through stimulation of IFN genes pathway activation, providing rationale for combination with immune checkpoint inhibitors. However, clinical evidence supporting this synergy remains limited. We conducted a neoadjuvant pilot study evaluating olaparib with or without pembrolizumab in homologous recombination deficiency (HRD)–positive advanced ovarian cancer. Patients and Methods: Patients with newly diagnosed, HRD-positive International Federation of Gynecology and Obstetrics stage III to IV high-grade serous or endometrioid ovarian cancer were enrolled. HRD status was determined using the Myriad MyChoice HRD Plus test. Patients received olaparib monotherapy (300 mg twice daily for 6 weeks; cohort 1, n = 10) or olaparib plus pembrolizumab (200 mg every 3 weeks for two cycles; cohort 2, n = 20), followed by surgery and platinum-based chemotherapy. The primary endpoint was the overall response rate (ORR). Exploratory IHC and single-cell RNA sequencing analyses assessed tumor microenvironmental changes. Results: The ORR was 50% [95% confidence interval (CI), 18.7–81.3] in cohort 1 and 70% (95% CI, 45.7–88.1) in cohort 2 (P = 0.2839). In cohort 1, responses occurred only in BRCA2-mutated tumors (5/5, 100%). In cohort 2, the ORR was 84.6% (11/13) in BRCA1/2-mutated tumors and 42.9% (3/7) in non–BRCA1/2-mutated tumors. Programmed cell death ligand 1 expression, tumor mutational burden, and microsatellite instability were not associated with response. Olaparib monotherapy did not increase tumor immunogenicity, whereas the combination increased CD8+ T-cell infiltration and immune-related transcriptional changes. No unexpected toxicities were observed. Conclusions: Neoadjuvant olaparib showed measurable radiographic activity in HRD-positive advanced ovarian cancer. Pembrolizumab enhanced immune activation, but its impact on early clinical response seemed limited.
- 30 July 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (20) , 4580-4591
Neoadjuvant Olaparib and Pembrolizumab Combination Therapy in the Treatment of Patients with HRD-Positive Advanced Ovarian Cancer: A Pilot Study
Purpose: Preclinical studies suggest that poly (ADP-ribose) polymerase inhibition enhances tumor immunogenicity through stimulation of IFN genes pathway activation, providing rationale for combination with immune checkpoint inhibitors. However, clinical evidence supporting this synergy remains limited. We conducted a neoadjuvant pilot study evaluating olaparib with or without pembrolizumab in homologous recombination deficiency (HRD)–positive advanced ovarian cancer. Patients and Methods: Patients with newly diagnosed, HRD-positive International Federation of Gynecology and Obstetrics stage III to IV high-grade serous or endometrioid ovarian cancer were enrolled. HRD status was determined using the Myriad MyChoice HRD Plus test. Patients received olaparib monotherapy (300 mg twice daily for 6 weeks; cohort 1, n = 10) or olaparib plus pembrolizumab (200 mg every 3 weeks for two cycles; cohort 2, n = 20), followed by surgery and platinum-based chemotherapy. The primary endpoint was the overall response rate (ORR). Exploratory IHC and single-cell RNA sequencing analyses assessed tumor microenvironmental changes. Results: The ORR was 50% [95% confidence interval (CI), 18.7–81.3] in cohort 1 and 70% (95% CI, 45.7–88.1) in cohort 2 (P = 0.2839). In cohort 1, responses occurred only in BRCA2-mutated tumors (5/5, 100%). In cohort 2, the ORR was 84.6% (11/13) in BRCA1/2-mutated tumors and 42.9% (3/7) in non–BRCA1/2-mutated tumors. Programmed cell death ligand 1 expression, tumor mutational burden, and microsatellite instability were not associated with response. Olaparib monotherapy did not increase tumor immunogenicity, whereas the combination increased CD8+ T-cell infiltration and immune-related transcriptional changes. No unexpected toxicities were observed. Conclusions: Neoadjuvant olaparib showed measurable radiographic activity in HRD-positive advanced ovarian cancer. Pembrolizumab enhanced immune activation, but its impact on early clinical response seemed limited.
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2-Positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (GENTLE-Z), a Randomized, Phase II Trial
- 1 November 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2-Positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (GENTLE-Z), a Randomized, Phase II Trial
- Open Access
- 7 March 2025
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 43 (7) , 1132-1144
CZT-based photon-counting-detector CT with deep-learning reconstruction: image quality and diagnostic confidence for lung tumor assessment
Purpose: This is a preliminary analysis of one of the secondary endpoints in the prospective study cohort. The aim of this study is to assess the image quality and diagnostic confidence for lung cancer of CT images generated by using cadmium–zinc–telluride (CZT)-based photon-counting-detector-CT (PCD-CT) and comparing these super-high-resolution (SHR) images with conventional normal-resolution (NR) CT images. Materials and methods: Twenty-five patients (median age 75 years, interquartile range 66–78 years, 18 men and 7 women) with 29 lung nodules overall (including two patients with 4 and 2 nodules, respectively) were enrolled to undergo PCD-CT. Three types of images were reconstructed: a 512 × 512 matrix with adaptive iterative dose reduction 3D (AIDR 3D) as the NRAIDR3D image, a 1024 × 1024 matrix with AIDR 3D as the SHRAIDR3D image, and a 1024 × 1024 matrix with deep-learning reconstruction (DLR) as the SHRDLR image. For qualitative analysis, two radiologists evaluated the matched reconstructed series twice (NRAIDR3D vs. SHRAIDR3D and SHRAIDR3D vs. SHRDLR) and scored the presence of imaging findings, such as spiculation, lobulation, appearance of ground-glass opacity or air bronchiologram, image quality, and diagnostic confidence, using a 5-point Likert scale. For quantitative analysis, contrast-to-noise ratios (CNRs) of the three images were compared. Results: In the qualitative analysis, compared to NRAIDR3D, SHRAIDR3D yielded higher image quality and diagnostic confidence, except for image noise (all P < 0.01). In comparison with SHRAIDR3D, SHRDLR yielded higher image quality and diagnostic confidence (all P < 0.01). In the quantitative analysis, CNRs in the modified NRAIDR3D and SHRDLR groups were higher than those in the SHRAIDR3D group (P = 0.003, DLR images provided the highest image quality and diagnostic confidence for lung tumor evaluation, followed by SHRAIDR3D and NRAIDR3D images. DLR demonstrated superior noise reduction compared to other reconstruction methods.
- 7 March 2025
- Published by Springer Nature in Japanese Journal of Radiology
- Vol. 43 (7) , 1132-1144
Open AccessCZT-based photon-counting-detector CT with deep-learning reconstruction: image quality and diagnostic confidence for lung tumor assessment
Purpose: This is a preliminary analysis of one of the secondary endpoints in the prospective study cohort. The aim of this study is to assess the image quality and diagnostic confidence for lung cancer of CT images generated by using cadmium–zinc–telluride (CZT)-based photon-counting-detector-CT (PCD-CT) and comparing these super-high-resolution (SHR) images with conventional normal-resolution (NR) CT images. Materials and methods: Twenty-five patients (median age 75 years, interquartile range 66–78 years, 18 men and 7 women) with 29 lung nodules overall (including two patients with 4 and 2 nodules, respectively) were enrolled to undergo PCD-CT. Three types of images were reconstructed: a 512 × 512 matrix with adaptive iterative dose reduction 3D (AIDR 3D) as the NRAIDR3D image, a 1024 × 1024 matrix with AIDR 3D as the SHRAIDR3D image, and a 1024 × 1024 matrix with deep-learning reconstruction (DLR) as the SHRDLR image. For qualitative analysis, two radiologists evaluated the matched reconstructed series twice (NRAIDR3D vs. SHRAIDR3D and SHRAIDR3D vs. SHRDLR) and scored the presence of imaging findings, such as spiculation, lobulation, appearance of ground-glass opacity or air bronchiologram, image quality, and diagnostic confidence, using a 5-point Likert scale. For quantitative analysis, contrast-to-noise ratios (CNRs) of the three images were compared. Results: In the qualitative analysis, compared to NRAIDR3D, SHRAIDR3D yielded higher image quality and diagnostic confidence, except for image noise (all P < 0.01). In comparison with SHRAIDR3D, SHRDLR yielded higher image quality and diagnostic confidence (all P < 0.01). In the quantitative analysis, CNRs in the modified NRAIDR3D and SHRDLR groups were higher than those in the SHRAIDR3D group (P = 0.003, DLR images provided the highest image quality and diagnostic confidence for lung tumor evaluation, followed by SHRAIDR3D and NRAIDR3D images. DLR demonstrated superior noise reduction compared to other reconstruction methods.